Joel Saltzman

711 total citations
34 papers, 395 citations indexed

About

Joel Saltzman is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Cancer Research. According to data from OpenAlex, Joel Saltzman has authored 34 papers receiving a total of 395 indexed citations (citations by other indexed papers that have themselves been cited), including 26 papers in Oncology, 17 papers in Pulmonary and Respiratory Medicine and 9 papers in Cancer Research. Recurrent topics in Joel Saltzman's work include Colorectal Cancer Treatments and Studies (8 papers), Lung Cancer Treatments and Mutations (8 papers) and Cancer Genomics and Diagnostics (7 papers). Joel Saltzman is often cited by papers focused on Colorectal Cancer Treatments and Studies (8 papers), Lung Cancer Treatments and Mutations (8 papers) and Cancer Genomics and Diagnostics (7 papers). Joel Saltzman collaborates with scholars based in United States, India and Australia. Joel Saltzman's co-authors include Smitha Krishnamurthi, Afshin Dowlati, David L. Bajor, Maryjo Prince‐Paul, Neal J. Meropol, Christopher J. Burant, Pingfu Fu, Joseph Gibbons, Joseph A. Bokar and Joanna M. Brell and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Joel Saltzman

32 papers receiving 381 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Joel Saltzman United States 12 230 124 93 79 46 34 395
Aik Seng Ng United Kingdom 7 176 0.8× 163 1.3× 71 0.8× 93 1.2× 44 1.0× 10 405
Bassim Al Bahrani Oman 12 207 0.9× 113 0.9× 90 1.0× 81 1.0× 49 1.1× 53 433
Troels Bechmann Denmark 13 217 0.9× 130 1.0× 89 1.0× 113 1.4× 49 1.1× 30 458
Pearl H. Seo United States 12 256 1.1× 161 1.3× 82 0.9× 116 1.5× 56 1.2× 18 563
Mary D. Chamberlin United States 10 260 1.1× 83 0.7× 108 1.2× 117 1.5× 39 0.8× 39 469
Patrick Cobb United States 14 301 1.3× 96 0.8× 105 1.1× 44 0.6× 41 0.9× 43 476
Hee-Chul Shin South Korea 9 164 0.7× 102 0.8× 72 0.8× 156 2.0× 23 0.5× 35 417
Maria Litwiniuk Poland 10 245 1.1× 117 0.9× 74 0.8× 98 1.2× 25 0.5× 52 442
Manjulika Das 8 134 0.6× 118 1.0× 69 0.7× 61 0.8× 31 0.7× 98 383
Tallal Younis Canada 15 331 1.4× 106 0.9× 118 1.3× 165 2.1× 80 1.7× 34 577

Countries citing papers authored by Joel Saltzman

Since Specialization
Citations

This map shows the geographic impact of Joel Saltzman's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Joel Saltzman with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Joel Saltzman more than expected).

Fields of papers citing papers by Joel Saltzman

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Joel Saltzman. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Joel Saltzman. The network helps show where Joel Saltzman may publish in the future.

Co-authorship network of co-authors of Joel Saltzman

This figure shows the co-authorship network connecting the top 25 collaborators of Joel Saltzman. A scholar is included among the top collaborators of Joel Saltzman based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Joel Saltzman. Joel Saltzman is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Yaeger, Rona, Nataliya V. Uboha, Samuel J. Klempner, et al.. (2025). Adagrasib (Ada) + cetuximab (Cetux) for KRAS G12C -mutated metastatic colorectal cancer (mCRC): Longer follow-up analysis from KRYSTAL-1.. Journal of Clinical Oncology. 43(4_suppl). 131–131. 1 indexed citations
2.
Yaeger, Rona, Nataliya V. Uboha, Tanios Bekaii‐Saab, et al.. (2024). Efficacy and Safety of Adagrasib plus Cetuximab in Patients with KRAS G12C-Mutated Metastatic Colorectal Cancer. Cancer Discovery. 14(6). 982–993. 44 indexed citations
3.
Otegbeye, Folashade, Brenda Cooper, Paolo F. Caimi, et al.. (2022). A Phase I Study to Determine the Maximum Tolerated Dose of ex Vivo Expanded Natural Killer Cells Derived from Unrelated, HLA-Disparate Adult Donors. Transplantation and Cellular Therapy. 28(5). 250.e1–250.e8. 19 indexed citations
4.
5.
Hue, Jonathan J., Erryk Katayama, Sarah C. Markt, et al.. (2021). A nationwide analysis of pancreatic cancer trial enrollment reveals disparities and participation problems. Surgery. 172(1). 257–264. 11 indexed citations
6.
7.
Douglas, Sara L., Polly Mazanec, Amy R. Lipson, et al.. (2021). Videoconference Intervention for Distance Caregivers of Patients With Cancer: A Randomized Controlled Trial. JCO Oncology Practice. 17(1). e26–e35. 15 indexed citations
8.
Hlubocky, Fay J., Tait D. Shanafelt, Anthony L. Back, et al.. (2021). Creating a Blueprint of Well-Being in Oncology: An Approach for Addressing Burnout From ASCO’s Clinician Well-Being Taskforce. American Society of Clinical Oncology Educational Book. 41(41). e339–e353. 21 indexed citations
9.
Eads, Jennifer R., Smitha Krishnamurthi, Joel Saltzman, et al.. (2020). Phase I clinical trial of temozolomide and methoxyamine (TRC-102), an inhibitor of base excision repair, in patients with advanced solid tumors. Investigational New Drugs. 39(1). 142–151. 10 indexed citations
10.
Fountzilas, Christos, Sarbajit Mukherjee, Joel Saltzman, et al.. (2020). P-156 A phase Ib/II study of cetuximab and pembrolizumab in metastatic colorectal cancer. Annals of Oncology. 31. S140–S140. 1 indexed citations
11.
Ramalingam, Suresh S., Suzanne E. Dahlberg, Chandra P. Belani, et al.. (2019). ECOG-ACRIN 5508: Pemetrexed, bevacizumab or the combination as maintenance therapy for advanced non-squamous NSCLC.. Journal of Clinical Oncology. 37(15_suppl). 9002–9002. 2 indexed citations
12.
13.
Ramalingam, Suresh S., Suzanne E. Dahlberg, Chandra P. Belani, et al.. (2019). Pemetrexed, Bevacizumab, or the Combination As Maintenance Therapy for Advanced Nonsquamous Non–Small-Cell Lung Cancer: ECOG-ACRIN 5508. Journal of Clinical Oncology. 37(26). 2360–2367. 43 indexed citations
14.
15.
McCourt, Carolyn K., Wei Deng, Don S. Dizon, et al.. (2016). A phase II evaluation of ixabepilone in the treatment of recurrent/persistent carcinosarcoma of the uterus, an NRG Oncology/Gynecologic Oncology Group study. Gynecologic Oncology. 144(1). 101–106. 5 indexed citations
16.
Hoimes, Christopher, Robert Abouassaly, Joel Saltzman, et al.. (2016). HCRN GU14-188: Neoadjuvant pembrolizumab (P) and gemcitabine (G) with or without cisplatin (C) in muscle invasive urothelial cancer (MIUC).. Journal of Clinical Oncology. 34(15_suppl). TPS4578–TPS4578. 8 indexed citations
17.
Eads, Jennifer R., Smitha Krishnamurthi, Joel Saltzman, et al.. (2015). Phase I clinical trial of temozolomide and methoxyamine (TRC-102) in patients with advanced solid tumors.. Journal of Clinical Oncology. 33(15_suppl). 2558–2558. 2 indexed citations
18.
Brell, Joanna M., Smitha Krishnamurthi, Milind Javle, et al.. (2008). A multi-center phase II study of oxaliplatin, irinotecan, and capecitabine in advanced gastric/gastroesophageal junction carcinoma. Cancer Chemotherapy and Pharmacology. 63(5). 851–857. 11 indexed citations
19.
Dowlati, Afshin, Shanmuga Subbiah, Matthew M. Cooney, et al.. (2007). Phase II trial of thalidomide as maintenance therapy for extensive stage small cell lung cancer after response to chemotherapy. Lung Cancer. 56(3). 377–381. 23 indexed citations
20.
Cooney, Matthew M., Subbiah Shanmugam, Graham Warren, et al.. (2005). Phase II trial of maintenance daily oral thalidomide in patients with extensive-stage small cell lung cancer (ES-SCLC) in remission. Journal of Clinical Oncology. 23(16_suppl). 7166–7166. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Aik Seng Ng Breakdown of academic impact, for papers by Bassim Al Bahrani Breakdown of academic impact, for papers by Troels Bechmann Breakdown of academic impact, for papers by Pearl H. Seo Breakdown of academic impact, for papers by Mary D. Chamberlin Breakdown of academic impact, for papers by Patrick Cobb Breakdown of academic impact, for papers by Hee-Chul Shin Breakdown of academic impact, for papers by Maria Litwiniuk Breakdown of academic impact, for papers by Manjulika Das Breakdown of academic impact, for papers by Tallal Younis
Rankless by CCL
2026